BioTuesdays

Tag - TLIS

Talis-Logo

BTIG cuts Talis Biomedical to neutral without PT

BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “neutral” from “buy” and removed its price target after president, CEO, director and co-founder, Brian Coe, stepped down from the board and executive. The stock closed...

Talis-Logo

BTIG starts Talis Biomedical at buy; PT $18

BTIG initiated coverage of point-of-care diagnostics company, Talis Biomedical, (NASDAQ:TLIS) with a “buy” rating and $18 price target. The stock closed at $12.95 on March 8. “Consistent with our checks with KOLs … we...